{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T15:32:10Z","timestamp":1749915130303},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of effective vaccines have been immensely welcomed by the world to prevent the transmission of SARS-CoV-2. However, the duration and clinical implications of antibody-mediated natural immunity in SARS-CoV-2 have not been adequately elucidated alongside some other immune system transforming factors. In a cohort study, we measured NAb titer following the 2nd immunization dosage of the CoviShield (AZD1222) vaccine<jats:italic>.<\/jats:italic> The enzyme-linked immunoassay was used to look for SARS-CoV-2\u2014specific NAb. We measured NAb at 30\u00a0days after the 2nd dosage of immunization and\u2009&gt;\u200996% titer was detected in 42.9% of subjects, but only 5.1% of subjects retained the same level after 180\u00a0days. The median NAb titer dropped significantly, from 92% at 30\u00a0days to 58% at 180\u00a0days (p\u2009&lt;\u20090.001). Besides, there were significant differences observed in NAb titer after 180\u00a0days by age, sex, COVID-19 infection, tobacco use, and asthma patients. However, SARS-CoV-2 infection along with two dosages of immunization upheld NAb titer (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) even at the end of the study period.<\/jats:p>","DOI":"10.1038\/s41598-022-18302-9","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T11:02:57Z","timestamp":1661770977000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population"],"prefix":"10.1038","volume":"12","author":[{"given":"Dipa","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Mosfequr","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaba Saha","family":"Chaity","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Abu","family":"Reza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariful","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"18302_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00522-7","author":"S Jakhmola","year":"2020","unstructured":"Jakhmola, S., Indari, O., Chatterjee, S. & Jha, H. C. SARS-CoV-2, an underestimated pathogen of the nervous system. SN Compr. Clin. Med. https:\/\/doi.org\/10.1007\/s42399-020-00522-7 (2020).","journal-title":"SN Compr. Clin. Med."},{"key":"18302_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta, D. & Vanelli, M. WHO declares COVID-19 a pandemic. Acta Biomed. 91, 157\u2013160. https:\/\/doi.org\/10.23750\/abm.v91i1.9397 (2020).","journal-title":"Acta Biomed."},{"key":"18302_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12941-021-00438-7","volume":"20","author":"SI Mallah","year":"2021","unstructured":"Mallah, S. I. et al. COVID-19: Breaking down a global health crisis. Ann. Clin. Microbiol. Antimicrob. 20, 35. https:\/\/doi.org\/10.1186\/s12941-021-00438-7 (2021).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"18302_CR4","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. USA 117, 9490\u20139496. https:\/\/doi.org\/10.1073\/pnas.2004168117 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"18302_CR5","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen, C. et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA 323, 1582\u20131589. https:\/\/doi.org\/10.1001\/jama.2020.4783 (2020).","journal-title":"JAMA"},{"key":"18302_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278. https:\/\/doi.org\/10.1126\/science.abc2241 (2020).","journal-title":"Science"},{"key":"18302_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73-84 e16. https:\/\/doi.org\/10.1016\/j.cell.2020.05.025 (2020).","journal-title":"Cell"},{"key":"18302_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124. https:\/\/doi.org\/10.1038\/s41586-020-2381-y (2020).","journal-title":"Nature"},{"key":"18302_CR9","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","volume":"1","author":"MS Suthar","year":"2020","unstructured":"Suthar, M. S. et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep. Med. 1, 100040. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100040 (2020).","journal-title":"Cell Rep. Med."},{"key":"18302_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2: Preliminary report. N. Engl. J. Med. 383, 1920\u20131931. https:\/\/doi.org\/10.1056\/NEJMoa2022483 (2020).","journal-title":"N. Engl. J. Med."},{"key":"18302_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science https:\/\/doi.org\/10.1126\/science.abf4063 (2021).","journal-title":"Science"},{"key":"18302_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442. https:\/\/doi.org\/10.1038\/s41586-020-2456-9 (2020).","journal-title":"Nature"},{"key":"18302_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1 (2021).","journal-title":"Lancet"},{"key":"18302_CR14","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162. https:\/\/doi.org\/10.1038\/s41467-021-21444-5 (2021).","journal-title":"Nat. Commun."},{"key":"18302_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135. https:\/\/doi.org\/10.1038\/s41586-021-03398-2 (2021).","journal-title":"Nature"},{"key":"18302_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963. https:\/\/doi.org\/10.1126\/science.abc7520 (2020).","journal-title":"Science"},{"key":"18302_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3201\/eid1103.040906","volume":"11","author":"NJ Temperton","year":"2005","unstructured":"Temperton, N. J. et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11, 411\u2013416. https:\/\/doi.org\/10.3201\/eid1103.040906 (2005).","journal-title":"Emerg. Infect. Dis."},{"key":"18302_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3201\/eid2307.170310","volume":"23","author":"PG Choe","year":"2017","unstructured":"Choe, P. G. et al. MERS-CoV antibody responses 1 year after symptom Onset, South Korea, 2015. Emerg. Infect. Dis. 23, 1079\u20131084. https:\/\/doi.org\/10.3201\/eid2307.170310 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"18302_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644. https:\/\/doi.org\/10.1038\/s41586-021-03207-w (2021).","journal-title":"Nature"},{"key":"18302_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJMc2032195","volume":"384","author":"AT Widge","year":"2021","unstructured":"Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80\u201382. https:\/\/doi.org\/10.1056\/NEJMc2032195 (2021).","journal-title":"N. Engl. J. Med."},{"key":"18302_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13293-020-00304-9","volume":"11","author":"C Gebhard","year":"2020","unstructured":"Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R. & Klein, S. L. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 11, 29. https:\/\/doi.org\/10.1186\/s13293-020-00304-9 (2020).","journal-title":"Biol. Sex Differ."},{"key":"18302_CR22","doi-asserted-by":"publisher","first-page":"e1008520","DOI":"10.1371\/journal.ppat.1008520","volume":"16","author":"Y Meng","year":"2020","unstructured":"Meng, Y. et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients. PLoS Pathog. 16, e1008520. https:\/\/doi.org\/10.1371\/journal.ppat.1008520 (2020).","journal-title":"PLoS Pathog."},{"key":"18302_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","volume":"588","author":"T Takahashi","year":"2020","unstructured":"Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315\u2013320. https:\/\/doi.org\/10.1038\/s41586-020-2700-3 (2020).","journal-title":"Nature"},{"key":"18302_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.18632\/oncotarget.13613","volume":"8","author":"F Qiu","year":"2017","unstructured":"Qiu, F. et al. Impacts of cigarette smoking on immune responsiveness: Up and down or upside down? Oncotarget 8, 268\u2013284. https:\/\/doi.org\/10.18632\/oncotarget.13613 (2017).","journal-title":"Oncotarget"},{"key":"18302_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"52","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971-977 e973. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.023 (2020).","journal-title":"Immunity"},{"key":"18302_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41467-020-14783-2","volume":"11","author":"Y Ou","year":"2020","unstructured":"Ou, Y., West, J. J., Smith, S. J., Nolte, C. G. & Loughlin, D. H. Air pollution control strategies directly limiting national health damages in the US. Nat. Commun. 11, 957. https:\/\/doi.org\/10.1038\/s41467-020-14783-2 (2020).","journal-title":"Nat. Commun."},{"key":"18302_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2021.02.007","volume":"558","author":"AS Abdel-Moneim","year":"2021","unstructured":"Abdel-Moneim, A. S., Abdelwhab, E. M. & Memish, Z. A. Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. Virology 558, 1\u201312. https:\/\/doi.org\/10.1016\/j.virol.2021.02.007 (2021).","journal-title":"Virology"},{"key":"18302_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424. https:\/\/doi.org\/10.1038\/s41579-021-00573-0 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"18302_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.virol.2021.09.001","volume":"563","author":"SY Gong","year":"2021","unstructured":"Gong, S. Y. et al. Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. Virology 563, 134\u2013145. https:\/\/doi.org\/10.1016\/j.virol.2021.09.001 (2021).","journal-title":"Virology"},{"key":"18302_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726. https:\/\/doi.org\/10.1038\/s41591-021-01294-w (2021).","journal-title":"Nat. Med."},{"key":"18302_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg3055","author":"NG Davies","year":"2021","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https:\/\/doi.org\/10.1126\/science.abg3055 (2021).","journal-title":"Science"},{"key":"18302_CR32","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1038\/s41467-020-19818-2","volume":"11","author":"L van Dorp","year":"2020","unstructured":"van Dorp, L. et al. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat. Commun. 11, 5986. https:\/\/doi.org\/10.1038\/s41467-020-19818-2 (2020).","journal-title":"Nat. Commun."},{"key":"18302_CR33","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1473-3099(21)00262-0","volume":"21","author":"M Ramanathan","year":"2021","unstructured":"Ramanathan, M., Ferguson, I. D., Miao, W. & Khavari, P. A. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect. Dis. 21, 1070. https:\/\/doi.org\/10.1016\/S1473-3099(21)00262-0 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"18302_CR34","doi-asserted-by":"publisher","first-page":"e068848","DOI":"10.1136\/bmj-2021-068848","volume":"375","author":"KJ Bruxvoort","year":"2021","unstructured":"Bruxvoort, K. J. et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: Test negative case-control study. BMJ 375, e068848. https:\/\/doi.org\/10.1136\/bmj-2021-068848 (2021).","journal-title":"BMJ"},{"key":"18302_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142\u2013146. https:\/\/doi.org\/10.1038\/s41586-021-03471-w (2021).","journal-title":"Nature"},{"key":"18302_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(22)00045-5","volume":"10","author":"PM McKeigue","year":"2022","unstructured":"McKeigue, P. M. et al. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): A case-control study. Lancet Respir. Med. 10, 566\u2013572. https:\/\/doi.org\/10.1016\/S2213-2600(22)00045-5 (2022).","journal-title":"Lancet Respir. Med."},{"key":"18302_CR37","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1056\/NEJMc2114290","volume":"385","author":"BY Reis","year":"2021","unstructured":"Reis, B. Y. et al. Effectiveness of BNT162b2 vaccine against delta variant in adolescents. N. Engl. J. Med. 385, 2101\u20132103. https:\/\/doi.org\/10.1056\/NEJMc2114290 (2021).","journal-title":"N. Engl. J. Med."},{"key":"18302_CR38","doi-asserted-by":"publisher","first-page":"S264","DOI":"10.1016\/j.mjafi.2021.06.032","volume":"77","author":"S Ghosh","year":"2021","unstructured":"Ghosh, S. et al. COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study. Med. J. Armed Forces India 77, S264\u2013S270. https:\/\/doi.org\/10.1016\/j.mjafi.2021.06.032 (2021).","journal-title":"Med. J. Armed Forces India"},{"key":"18302_CR39","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","volume":"397","author":"A Sheikh","year":"2021","unstructured":"Sheikh, A. et al. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461\u20132462. https:\/\/doi.org\/10.1016\/S0140-6736(21)01358-1 (2021).","journal-title":"Lancet"},{"key":"18302_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J. & Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. 28, 202\u2013221. https:\/\/doi.org\/10.1016\/j.cmi.2021.10.005 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"18302_CR41","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jmv.27526","volume":"94","author":"S Kumar","year":"2022","unstructured":"Kumar, S., Thambiraja, T. S., Karuppanan, K. & Subramaniam, G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J. Med. Virol. 94, 1641\u20131649. https:\/\/doi.org\/10.1002\/jmv.27526 (2022).","journal-title":"J. Med. Virol."},{"key":"18302_CR42","doi-asserted-by":"publisher","first-page":"781429","DOI":"10.3389\/fcimb.2021.781429","volume":"11","author":"SM Hirabara","year":"2021","unstructured":"Hirabara, S. M. et al. SARS-COV-2 variants: Differences and potential of immune evasion. Front. Cell Infect. Microbiol. 11, 781429. https:\/\/doi.org\/10.3389\/fcimb.2021.781429 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"18302_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/d41586-021-03614-z","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway, E. & Ledford, H. How bad is Omicron? What scientists know so far. Nature 600, 197\u2013199. https:\/\/doi.org\/10.1038\/d41586-021-03614-z (2021).","journal-title":"Nature"},{"key":"18302_CR44","doi-asserted-by":"publisher","first-page":"752233","DOI":"10.3389\/fimmu.2021.752233","volume":"12","author":"H Ali","year":"2021","unstructured":"Ali, H. et al. Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination. Front. Immunol. 12, 752233. https:\/\/doi.org\/10.3389\/fimmu.2021.752233 (2021).","journal-title":"Front. Immunol."},{"key":"18302_CR45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817. https:\/\/doi.org\/10.1126\/science.abc4776 (2020).","journal-title":"Science"},{"key":"18302_CR46","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.abc5343","volume":"369","author":"W Deng","year":"2020","unstructured":"Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369, 818\u2013823. https:\/\/doi.org\/10.1126\/science.abc5343 (2020).","journal-title":"Science"},{"key":"18302_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381. https:\/\/doi.org\/10.1126\/science.abc1932 (2020).","journal-title":"Science"},{"key":"18302_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.chom.2020.04.019","volume":"27","author":"K Subbarao","year":"2020","unstructured":"Subbarao, K. SARS-CoV-2: A new song recalls an old melody. Cell Host Microbe 27, 692\u2013694. https:\/\/doi.org\/10.1016\/j.chom.2020.04.019 (2020).","journal-title":"Cell Host Microbe"},{"key":"18302_CR49","doi-asserted-by":"publisher","first-page":"576818","DOI":"10.3389\/fimmu.2020.576818","volume":"11","author":"M Abu-Farha","year":"2020","unstructured":"Abu-Farha, M. et al. Impact of diabetes in patients diagnosed with COVID-19. Front. Immunol. 11, 576818. https:\/\/doi.org\/10.3389\/fimmu.2020.576818 (2020).","journal-title":"Front. Immunol."},{"key":"18302_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mam.2012.10.002","volume":"34","author":"CN Lumeng","year":"2013","unstructured":"Lumeng, C. N. Innate immune activation in obesity. Mol. Aspects Med. 34, 12\u201329. https:\/\/doi.org\/10.1016\/j.mam.2012.10.002 (2013).","journal-title":"Mol. Aspects Med."},{"key":"18302_CR51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.dsx.2020.12.035","volume":"15","author":"R Pal","year":"2021","unstructured":"Pal, R. et al. Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report. Diab. Metab. Syndr. 15, 193\u2013196. https:\/\/doi.org\/10.1016\/j.dsx.2020.12.035 (2021).","journal-title":"Diab. Metab. Syndr."},{"key":"18302_CR52","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/vaccines9020102","volume":"9","author":"J Perez-Galarza","year":"2021","unstructured":"Perez-Galarza, J. et al. Immune response to SARS-CoV-2 infection in obesity and T2D: Literature review. Vaccines 9, 102. https:\/\/doi.org\/10.3390\/vaccines9020102 (2021).","journal-title":"Vaccines"},{"key":"18302_CR53","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263. https:\/\/doi.org\/10.1126\/science.abb2507 (2020).","journal-title":"Science"},{"key":"18302_CR54","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1056\/NEJMc070348","volume":"357","author":"WC Cao","year":"2007","unstructured":"Cao, W. C., Liu, W., Zhang, P. H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162\u20131163. https:\/\/doi.org\/10.1056\/NEJMc070348 (2007).","journal-title":"N. Engl. J. Med."},{"key":"18302_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/jmv.20431","volume":"77","author":"JS Zhang","year":"2005","unstructured":"Zhang, J. S. et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J. Med. Virol. 77, 147\u2013150. https:\/\/doi.org\/10.1002\/jmv.20431 (2005).","journal-title":"J. Med. Virol."},{"key":"18302_CR56","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211. https:\/\/doi.org\/10.1038\/s41591-021-01377-8 (2021).","journal-title":"Nat. Med."},{"key":"18302_CR57","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"JH Ko","year":"2018","unstructured":"Ko, J. H. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir. Ther. 23, 617\u2013622. https:\/\/doi.org\/10.3851\/IMP3243 (2018).","journal-title":"Antivir. Ther."},{"key":"18302_CR58","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jadohealth.2020.06.025","volume":"67","author":"SH Adams","year":"2020","unstructured":"Adams, S. H., Park, M. J., Schaub, J. P., Brindis, C. D. & Irwin, C. E. Jr. Medical vulnerability of young adults to severe COVID-19 illness-data from the national health interview survey. J. Adolesc. Health 67, 362\u2013368. https:\/\/doi.org\/10.1016\/j.jadohealth.2020.06.025 (2020).","journal-title":"J. Adolesc. Health"},{"key":"18302_CR59","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/s0950268800048019","volume":"105","author":"KA Callow","year":"1990","unstructured":"Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435\u2013446. https:\/\/doi.org\/10.1017\/s0950268800048019 (1990).","journal-title":"Epidemiol. Infect."},{"key":"18302_CR60","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/jmv.27524","volume":"94","author":"SK Saxena","year":"2022","unstructured":"Saxena, S. K. et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J. Med. Virol. 94, 1738\u20131744. https:\/\/doi.org\/10.1002\/jmv.27524 (2022).","journal-title":"J. Med. Virol."},{"key":"18302_CR61","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.4049\/jimmunol.2000839","volume":"205","author":"N Baumgarth","year":"2020","unstructured":"Baumgarth, N., Nikolich-Zugich, J., Lee, F. E. & Bhattacharya, D. Antibody responses to SARS-CoV-2: Let\u2019s stick to known knowns. J. Immunol. 205, 2342\u20132350. https:\/\/doi.org\/10.4049\/jimmunol.2000839 (2020).","journal-title":"J. Immunol."},{"key":"18302_CR62","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996-1012 e1019. https:\/\/doi.org\/10.1016\/j.cell.2020.09.038 (2020).","journal-title":"Cell"},{"key":"18302_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","volume":"53","author":"A Sariol","year":"2020","unstructured":"Sariol, A. & Perlman, S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity 53, 248\u2013263. https:\/\/doi.org\/10.1016\/j.immuni.2020.07.005 (2020).","journal-title":"Immunity"},{"key":"18302_CR64","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1126\/science.abd7728","volume":"370","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227\u20131230. https:\/\/doi.org\/10.1126\/science.abd7728 (2020).","journal-title":"Science"},{"key":"18302_CR65","doi-asserted-by":"publisher","first-page":"2000688","DOI":"10.1183\/13993003.00688-2020","volume":"55","author":"JM Leung","year":"2020","unstructured":"Leung, J. M. et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19. Eur. Respir. J. 55, 2000688. https:\/\/doi.org\/10.1183\/13993003.00688-2020 (2020).","journal-title":"Eur. Respir. J."},{"key":"18302_CR66","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N Engl. J. Med. 384, 1466\u20131468. https:\/\/doi.org\/10.1056\/NEJMc2102017 (2021).","journal-title":"N Engl. J. Med."},{"key":"18302_CR67","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622. https:\/\/doi.org\/10.1038\/s41586-021-03324-6 (2021).","journal-title":"Nature"},{"key":"18302_CR68","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJMc2102179","volume":"384","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N. Engl. J. Med. 384, 1468\u20131470. https:\/\/doi.org\/10.1056\/NEJMc2102179 (2021).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18302-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T11:21:20Z","timestamp":1661772080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18302-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18302"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18302-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14681"}}